{"disease":{"id":"chronic-inflammatory-demyelinating-polyneuropathy-cidp","name":"chronic inflammatory demyelinating polyneuropathy cidp"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06040567","title":"Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","phase":"","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04281472","title":"A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":322,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT04280718","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":229,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT06858722","title":"Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":175,"lead_sponsor_name":"Zhongming Qiu","has_results":false},{"nct_id":"NCT02027701","title":"Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT07337785","title":"CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Daishi Tian","has_results":false},{"nct_id":"NCT03166527","title":"Panzyga in CIDP Administered at Different Infusion Rates","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Vera Bril","has_results":false},{"nct_id":"NCT03684018","title":"Two Dose Levels of Privigen in Pediatric CIDP","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT05492604","title":"Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.","phase":"NA","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT07526493","title":"Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04777734","title":"Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT05014724","title":"CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}